Unidad de Bioquímica, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
Facultad de Ciencias, Universidad Nacional Autónoma de México (UNAM), Mexico City, Mexico.
Front Immunol. 2023 Jan 9;13:987231. doi: 10.3389/fimmu.2022.987231. eCollection 2022.
Antimicrobial resistance (AMR) is a global health problem that causes more than 1.27 million deaths annually; therefore, it is urgent to focus efforts on solving or reducing this problem. The major causes of AMR are the misuse of antibiotics and antimicrobials in agriculture, veterinary medicine, and human medicine, which favors the selection of drug-resistant microbes. One of the strategies proposed to overcome the problem of AMR is to use polyvalent human immunoglobulin or IVIG. The main advantage of this classic form of passive immunization is its capacity to enhance natural immunity mechanisms to eliminate bacteria, viruses, or fungi safely and physiologically. Experimental data suggest that, for some infections, local administration of IVIG may produce better results with a lower dose than intravenous application. This review presents evidence supporting the use of polyvalent human immunoglobulin in AMR, and the potential and challenges associated with its proposed usage.
抗微生物药物耐药性（AMR）是一个全球性的健康问题，每年导致超过 127 万人死亡；因此，迫切需要集中精力解决或减少这一问题。AMR 的主要原因是抗生素和抗菌药物在农业、兽医和人类医学中的滥用，这有利于选择耐药微生物。为克服 AMR 问题而提出的策略之一是使用多价人免疫球蛋白或 IVIG。这种经典形式的被动免疫的主要优势是其能够增强天然免疫机制，安全且生理性地消除细菌、病毒或真菌。实验数据表明，对于某些感染，IVIG 的局部给药可能会产生更好的效果，且剂量低于静脉应用。本综述介绍了支持在 AMR 中使用多价人免疫球蛋白的证据，以及与其使用相关的潜力和挑战。
